scout

All News

WASHINGTON-Overall cancer incidence and mortality have continued to decline in the United States, but incidences of some cancers continue to rise, and significant differences in both incidence and mortality persist among different racial and ethnic groups.

WASHINGTON-During the past 16 years, researchers have developed data that suggest cannabinoid-based drugs may be effective for a variety of medical uses, including pain relief, antiemesis, and appetite stimulation in cancer patients, an Institute of Medicine (IOM) committee has concluded. It warned, however, that such medical uses carry some risks, particularly the harmful effects of smoking marijuana, which it discouraged as a means of delivering medications.

Discovery of a marker that allows tracking of thymus function also shows how the adult immune system might repair itself after being damaged by the human immunodeficiency virus (HIV), UT Southwestern Medical Center at Dallas scientists report

ROCKVILLE, Md-Two cancer-related topics are among four new evaluations the Agency for Health Care Policy and Research (AHCPR) has asked the U.S. Preventive Services Task Force to make. The task force is an independent panel of preventive health experts that evaluates the effectiveness of a wide range of clinical preventive services.

BETHESDA, Md-The National Cancer Institute (NCI) has earmarked $30 million for use over the next 5 years to support a group of projects that will unite research scientists and community leaders in efforts to address disparities in national cancer rates among minorities and other underserved groups.

ALEXANDRIA, Va-“The Health Care Finance Agency’s plan to reimburse for outpatient Medicare cancer treatment according to ambulatory payment classifications (APCs) would have a crippling effect on research and development of new drug therapies and lower the quality of care for present and future cancer patients,” Congressman Gene Green, Representative of the 29th District of Texas in the US House of Representatives, said at the Annual Meeting of the Association of Community Cancer Centers (ACCC).

BETHESDA, Md-The first human trials of the antiangiogenesis drug endostatin will take place at the University of Wisconsin-Madison and the University of Texas M.D. Anderson Cancer Center. The National Cancer Institute (NCI), which will sponsor the phase I trials, said that the studies will begin in late summer or early fall. Protocols for the two studies had not been worked out at the time of the NCI’s announcement.

Champlin et al review a most interesting topic that has emerged recently; namely, the use of nonmyeloablative conditioning regimens to induce immune-mediated graft-vs-leukemia (GVL) effects, or, in a more general sense, graft-vs-tumor (GVT)

While in Denmark under an ASTRO/ESTRO fellowship travel grant, Dr. Brian Kavanagh spoke with a number of oncologists at the University of Aarhus about their research and the practice of oncology in Denmark. In this essay, he skillfully weaves Danish history, philosophy, customs, and landscape into his interviews with four eminent Danish physicians.

In his 1975 New England Journal of Medicine review article on bone marrow transplantation, Nobel laureate E. Donnall Thomas listed the major obstacles to successful transplantation as donor availability, graft-vs-host disease (GVHD), treatment-

ATLANTA-In 1995, an estimated 47 million adults in the United States were current smokers. A “Profile of Smokers” from the American Cancer Society’s Cancer Facts & Figures-1999 shows that, in that year, smoking prevalence was higher for men (27%) than women (22.6%) and highest among American Indians/Alaskan natives (36.2%), compared with other racial and ethnic groups.